Other Events ·
Rocket Pharmaceuticals, Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large…
RCKTRocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company on June 10, 2026, receiving $180.0 million in gross proceeds. The voucher was issued following the FDA approval of KRESLADI (marnetegragene autotemcel) for treating pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). Rocket Pharmaceuticals, Inc. is a biotechnology company developing gene therapies for rare pediatric diseases.